CONNEQT Health Limited engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific. It offers SphygmoCor, a vascular biometric technology that captures central hemodynamics and arterial stiffness for noninvasive measurement of vascular biomarkers including central aortic pressures and arterial stiffness indices. The company also provides medical devices and vascular biomarkers for hypertension, cardiovascular disease, and other vascular health disorders; and develops and sells medical devices, digital solutions, and wearables, home health, decentralized clinical trials, and remote patient monitoring. It sells its cardiovascular devices and services to hospitals, clinics, research institutions, and pharmaceutical companies. The company was formerly known as CardieX Limited and changed its name to CONNEQT Health Limited in September 2025. CONNEQT Health Limited was founded in 1994 and is based in Sydney, Australia.
Metrics to compare | CQT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCQTPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.9x | −6.2x | −0.7x | |
PEG Ratio | 0.02 | −0.03 | 0.00 | |
Price/Book | 27.2x | 3.6x | 2.6x | |
Price / LTM Sales | 2.8x | 6.3x | 3.4x | |
Upside (Analyst Target) | - | 60.0% | 37.8% | |
Fair Value Upside | Unlock | −1.2% | 5.5% | Unlock |